Additional analysis is needed to assess the safety profile of St. Jude Medical Inc.’s Amplatzer and WL Gore & Associates Inc.’s Gore Helex transcatheter atrial septal defect (ASD) occluders in light of post-market adverse event data pointing to unexpected rates of tissue erosion and device fracture, FDA’s Circulatory System Devices Panel concluded May 24.
Chief among the panel’s recommendations is that FDA should order St. Jude to conduct a “section 522” post-market surveillance study with a prospective, case-controlled design to gain a better understanding of what might be driving the roughly 0
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?